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Abstract
Background: SCCHN is the sixth most common cancer worldwide. Locally advanced SCCHN continues to be a
therapeutic challenge with high rates of morbidity and mortality and a low cure rate. Despite the apparent impact
of SCCHN on patients and presumably society, the economic burden of the treatment of resected SCCHN patients
in the UK has not been investigated.
Methods: This retrospective data analysis was based on in- and outpatient care records extracted from Hospital
Episode Statistic database and linked to mortality data in the UK. SCCHN patients with resection of lip, tongue, oral
cavity, pharynx or larynx were followed for at least one year (max. of 5 years) from the date of first resection.
Results: A total of 11,403 patients (mean age 63.2 years, 69.8% males) who met study criteria were followed for an
average of 31 months. 32.3% of patients died in the follow-up period and the mean time to death was 16.9
months. In the first year, mean number of days of hospitalization and number of outpatient visits was 21.6 and 4.2,
respectively; mean number of reconstructive and secondary surgeries was 0.32 and 0.14 per patient, respectively;
4.7% of the patients received radiotherapy and 12.2% received chemotherapy. From the second to fifth year
healthcare utilizations rates were lower. Mean cost of post-operative healthcare utilization was £23,212 over 5 years
(£19,778 for the first year and £1477, £847, £653 and £455 for years 2-5). Total cost of post-operative healthcare
utilisation was estimated to be £255.5 million over the 5-year follow-up.
Conclusions: In the UK, SCCHN patients after surgical resection needed considerable healthcare resources and
incurred substantial costs. Study findings might provide a useful source for clinicians and decision makers in
understanding the economic burden of managing SCCHN in the UK and also suggests a need for new therapies
that could improve outcomes and reduce the disease burden.
Keywords: Squamous cell carcinoma of head and neck, Head and neck cancer, Oral cancer, Resection, Surgery,
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Background
Head and neck cancer (HNC) is a group of biologically
similar cancers originating from the upper aerodigestive
tract at various sites including the lips, oral cavity, nasal
cavity, salivary glands, paranasal sinuses, thyroid, pharynx,
and larynx. In the last 10 years, HNC has been one of the
10 most frequently diagnosed malignancies worldwide,
with more than 640,000 people diagnosed and causing
7,500 deaths yearly [1]. In the UK, 7,538 people were
newly diagnosed with HNC in 2006 and 2,594 people died
from the disease in 2007 [2]. Recent trend studies
reported that the incidence of HNC has risen over the last
20 years in the UK [3-7]. One of the findings showed that
the incidence rate of oral and oropharyngeal cancer rose
from 6.5 to 8.3 per 100,000 men and from 2.6 to 3.6 per
100,000 women between 1990–1999 [3]. According to a
study of mortality in oral cancer in Europe, the age
adjusted mortality rate in England and Wales was 2.7 and
1.05 per 100,000 inhabitants in men and women respec-
tively and in Scotland the age adjusted mortality rate was
4.6 and 1.6 per 100,000 inhabitants in men and women,
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major cancers in the UK during 2006-2025, the mortality
rate for oral cancer was estimated to still be growing in
men and to be nearly constant in women [9].
The treatment of squamous cell carcinoma of the head
and neck (SCCHN) is complex, partly because of the
variety of tumor subsites and also because of the ana-
tomic constraints of the head and neck region, together
with the importance of maintaining organ function.
Approximately 30–40% of patients with SCCHN present
an early stage disease which is commonly managed by
surgery (referred to as resection) or adjuvant radiother-
apy with curative intent. For patients with advanced
locoregionally disease without distant metastases, combi-
nations of surgery, radiotherapy, and chemotherapy are
used with the objective to maximize cure and maintain
functional status through organ preservation. For patients
with unresectable SCCHN, concurrent chemoradiother-
apy is often chosen as a palliative treatment and may
result in improved survival.
Although therapeutic advances have expanded treat-
ment options, surgical resection is still considered an
important treatment modality for SCCHN. The traditional
treatment modality with surgical resection has a poor
prognosis, 10–15% risk for local disease recurrence and
20–30% risk for disease progression within one year of
treatment. According to a population-based study in Den-
mark, 1-year relative survival of patients with oral and
pharynx cancer was 70% and 73% and the 5-year relative
survival was 33% and 42% in men and women respectively
[10]. Besides, surgery for oral cavity and oropharynx can-
cer was found to immediately cause impairment in physi-
cal, emotional and social functions and severely
compromise the patient’s quality of life (QoL) [11]. Over-
all QoL scores of patients with SCCHN were significantly
worse at 3 and 6 months and returned to around preo-
perative scores at 12 months after treatment [12,13].
However, the patients with oral cancer, who were treated
with surgery, did not restore preoperational level of func-
tion in appearance, swallowing, recreation, and chewing
[14-16] and no significant overall improvement was found
at 12 months among patients who underwent free-flap
surgery or total laryngectomy [17-22]. Finally, the treat-
ment is burdensome on those who survive. According to
findings from registry data among SCCHN patients after
treatment, 55% patients had a feeding tube placed, 13%
needed a tracheotomy, 79% required opioid analgesics,
and 78% had anti-emetics prescribed, and 34% reported
grade 3–4 mucositis/stomatitis [23].
Despite the apparent impact of the disease on patients
and presumably on society and health care, the eco-
nomic burden of the treatment of resected SCCHN
patients in the UK has not been investigated. Therefore,
this study aimed at identifying the post-operative
healthcare utilisation and its associated cost for an inci-
dent cohort of patients with SCCHN in the UK who
underwent surgical resection.
Methods
A retrospective analysis was performed by using Hospital
Episode Statistic (HES) data, which covers all National
Health Service (NHS) trusts and independent sectors in
the UK. The scope of the data included secondary care
facilities such as care trusts, mental health trust, NHS
trust, ambulance trusts and emergency and urgent care
but it did not include primary care facilities such as NHS
direct/clinic centers, GP practices, dentists, opticians and
pharmacists and also did not include accident and emer-
gency care. The NHS data quality report concluded that
HES data was a reliable source for activity-based analyses
at national level in a provider’s perspective based on high
levels of completeness and validity for most fields related
to patient identification in both inpatient and outpatient
care [24]. However, the HES accident and emergency data
still needs to be attested with reliability of the data [25] so
it was not used in this analysis. The healthcare utilisation
for patients in the HES data was identified with OPCS-4.5
codes which stores up individual procedures and interven-
tions provided from inpatient and outpatient care. Mortal-
ity data between 2003 and 2009, provided by the Office for
National Statistics (ONS), was used to identify deceased
patients in the HES data. The requested data from HES
and ONS were anonymized records, thus no patient’s
identity were disclosed for the purposes of this analysis.
The HES data was extracted from April 1, 2003 to
March 31, 2009 and the data included patients who met
the following inclusion criteria; evidence of cancer as pri-
mary diagnosis in lip, tongue, oral cavity, pharynx or lar-
ynx (ICD-10: C00–6, C09–10, C12–4, C32) and evidence
of surgical resection from July 1, 2003 to March 31, 2008.
The surgical resection was defined as including incision,
excision, removal of foreign body, extirpation or -ectomy
in respiratory tract, mouth, skin, soft tissue or bones and
joints of skull of the patients. The selected patients were
followed from the earliest date (index date) with the pro-
cedure code for primary surgical resection for at least 12
months or to the date of death or at the latest March 31,
2009. Patients who underwent resection between April 1,
2003 and June 30, 2003 were excluded to ensure that the
patient would not be followed from a secondary resection.
Patients under the age of 18 years were excluded. Figure 1
depicts the study observation period.
Post-operative healthcare utilization included the num-
ber of days of hospitalisation, the number of visits in out-
patient care and treatments for chemotherapy-related
adverse events. The chemotherapy-related treatments
were identified by an episode of disease including anemia,
neutropenia, thrombocytopenia, nausea, mucositis and
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healthcare utilization also included the number of radio-
therapy and chemotherapy sessions and secondary or
reconstructive surgeries after resection. The secondary
surgery was defined as resection following a primary
resection. The reconstructive resection was defined as
including plasty, plastic repair, reconstruction, and flap in
respiratory tract, mouth, skin, soft tissue or bones and
joints of skull of the patients.
The post-operative healthcare cost was measured by
mapping the healthcare utilization to “the national sche-
dule of reference costs 2008–09 for NHS Trusts” and
“Unit costs of health & social care 2009” published by the
Personal Social Services Research Unit (PSSRU). The
unit costs for each procedure from inpatient and outpati-
ent care are described in Additional file 1.
To account for the censored patients due to different
lengths of follow-up in the data, the Kaplan-Meier sam-
ple-average (KMSA) method was employed. The KMSA
i sat e c h n i q u et op r o v i d eac o n s i s t e n te s t i m a t o ro fc o s t s
in the presence of censoring in the sample population
[26]. The follow-up period was divided into each year
and the mean cost of all uncensored patients during the
each year was multiplied by the Kaplan-Meier estimate of
the proportion alive at the beginning of the each year.
Summing across these weighted costs for each interval
resulted in the adjusted costs for censoring. The health-
care utilization and its costs were calculated in the first,
second, third, fourth and fifth year from resection. The
utilization and costs were to be interpreted as per year in
the follow-up period for a group of the patients (incident
cases) who were followed more than 1 year and less than
5 years.
Results
A total of 38,460 patients who were diagnosed with
SCCHN from April 1, 2003 to March 31, 2009 were
extracted from the HES data. 14,764 patients (38.4%)
underwent a surgical resection. Among the resected
patients, we excluded 739 patients who underwent resec-
tion between April 1 and June 30, 2003. 2,599 patients
who underwent resection after March 31, 2008 were also
excluded as they had less than 12 months follow-up from
the first resection. After excluding a further 23 patients,
who were under the age of 18 years, 11,403 patients were
finally included in the sample population. Figure 2 pre-
sents the flow chart for selection of the incident cohort
of patients included in this study.
Patient Cohort Characteristics
T h em e a na g eo ft h ep a t i e n tc o h o r tf o rt h i ss t u d yw a s
63.2 years (SD 12.6) and 69.8% of patients were men. The
mean age, the ratio of men to women and the proportion
of age groups in the population corresponded to UK inci-
dence statistics for HNC reported by Cancer Research
UK [27,28]. Lip cancer patients were the oldest (mean
69.6 years) compared to the other four cancer sites while
the larynx cancer subgroup had the largest percentage of
males (85%). The mean length of follow-up was 31.0
months (SD 18.4). The HES data were extracted mainly
Figure 1 Study observation period.
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patients in the population came from England and there
were a minority from Scotland, Wales and Northern Ire-
land. Larynx cancer patients accounted for 29% and
pharynx cancer patients for 20% of the cohort. Oral cav-
ity, tongue and lip cancers patients accounted for 21%,
19% and 11%, respectively (Table 1). A total of 3,686
deaths were identified during follow-up and the mean
length from first resection to death was 16.9 months.
46.3% of the deaths occurred within the first year of fol-
low up with the highest and lowest percentage of deaths
occurring with the pharyngeal (47.9%) and lip cancer
(31.5%) cohorts, respectively. The highest percentage of
deaths occurred among larynx cancer patients (37.3%),
followed by pharynx (35.4%), oral cavity (32.7%), tongue
(30.3%) and lip cancer patients (16.2%) (Table 2).
Estimation of survival over 5-year follow-up
To calculate the total cost of the post-operative health-
care utilisation over the 5-year follow-up, the number of
surviving patients during the 5-year follow-up was esti-
mated, based on the number of followed patients and
the number of deaths in the population. The number of
surviving patients was assumed to be equal to the num-
ber of patients surviving the previous year deducted by
the number of deaths among both the followed patients
and the censored patients at the previous year. The
number of deaths among the censored patients was esti-
mated by the proportion of deaths in the followed
patients multiplied with the number of the censored
patients. At the beginning of the follow-up, there were
11,403 patients in the cohort. Since all subjects were fol-
lowed at least 1 year, there was no censored patient and
there were 9,697 surviving patients at the beginning of
the second year in the cohort. The number of surviving
patient per the rest of year was estimated as described
(Table 3). The total cost of the post-operative healthcare
utilisation was calculated by multiplying the mean costs
in each year with the number of surviving patients in
each year.
Post-operative healthcare utilisation
In the first year, the mean number of days of hospitalisa-
tion was 21.6 and the mean number of outpatient visits
Figure 2 Sample selection and attrition flow chart.
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surgeries was 0.32 per patient and the number of second-
ary surgeries was 0.14 per patient. 4.7% of the patients
received radiotherapy and 12.2% of the patients received
chemotherapy in either an inpatient or outpatient setting.
There were a total of 5,152 radiotherapy sessions and
5,153 chemotherapy sessions in inpatient and outpatient
care. Half of the patients treated with chemotherapy
were admitted due to chemotherapy-related conditions
(Figure 3, 4).
Table 1 Patient cohort characteristics
Cancer site Lip Tongue Oral cavity Pharynx Larynx SCCHN
N%N%N%N%N%N %
1,250 11.0 2,167 19.0 2,372 20.8 2,304 20.2 3,310 29.0 11,403 100.0
Gender (Male) 726 58.1 1,267 58.5 1,436 60.5 1,717 74.5 2,813 85.0 7,959 69.8
Age group
18-44 72 5.8 213 9.8 159 6.7 230 10.0 86 2.6 760 6.7
45-64 328 26.2 1,062 49.0 1,221 51.5 1,459 63.3 1,499 45.3 5,569 48.8
65+ 849 67.9 892 41.2 991 41.8 615 26.7 1,725 52.1 5,072 44.5
Geographic location
North East 96 7.7 109 5.0 167 7.0 160 6.9 280 8.5 812 7.1
North West 214 17.1 332 15.3 447 18.8 399 17.3 548 16.6 1,940 17.0
Merseyside 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Yorkshire and
Humber
121 9.7 225 10.4 276 11.6 256 11.1 375 11.3 1,253 11.0
East Midlands 112 9.0 212 9.8 245 10.3 244 10.6 269 8.1 1,082 9.5
West Midlands 92 7.4 206 9.5 228 9.6 170 7.4 300 9.1 996 8.7
East of England 147 11.8 204 9.4 185 7.8 207 9.0 304 9.2 1,047 9.2
London 134 10.7 280 8.3 291 12.3 269 11.7 431 13.0 1,305 11.4
South East 169 13.5 338 15.6 279 11.8 289 12.5 437 13.2 1,512 13.3
South West 156 12.5 225 10.4 209 8.8 272 11.8 302 9.1 1,164 10.2
Scotland 1 0.1 4 0.2 4 0.2 2 0.1 0 0.0 11 0.1
No fixed above 0 0.0 2 0.1 0 0.0 3 0.1 2 0.1 7 0.1
Wales 6 0.5 9 0.4 12 0.5 16 0.7 13 0.4 56 0.5
Foreign (including
Isle of Man and
Channel Islands)
1 0.0 18 0.8 21 0.9 14 0.6 40 1.2 93 0.8
Unknown 1 0.0 3 0.1 8 0.3 3 0.1 8 0.2 22 0.2
Northern Ireland 0 0.0 0 0.0 0 0.0 0 0.0 1 0.0 1 0.0
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age 69.6 13.9 61.8 13.7 62.8 12.5 58.3 11.1 65.4 10.7 63.2 12.6
Length of follow-up (months) 34.9 16.9 31.4 18.3 30.8 18.5 30.1 18.3 30 18.7 31 18.4
1 months
Table 2 Number of deaths identified by year and cancer type
Cancer site Lip Tongue Oral cavity Pharynx Larynx SCCHN
(N = 1,250) (N = 2,167) (N = 2,372) (N = 2,304) (N = 3,310) (N = 11,403)
Length of time to death
1,2 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
22.4 15.3 16.4 13.3 17.4 14.1 16.4 13.4 16.4 13.6 16.9 13.8
Number of deaths
3 N%N%N%N%N%N %
203 16.2 656 30.3 776 32.7 815 35.4 1,236 37.3 3,686 32.3
1 year 64 31.5 310 47.3 360 46.4 390 47.9 582 47.1 1,706 46.3
2 year 60 29.6 197 30.0 213 27.4 230 28.2 344 27.8 1,044 28.3
3 year 36 17.7 82 12.5 105 13.5 117 14.4 180 14.6 520 14.1
4 year 27 13.3 47 7.2 65 8.4 51 6.3 84 6.8 274 7.4
5 year 16 7.9 20 3.0 33 4.3 27 3.3 46 3.7 142 3.9
1 months;
2 among the deceased patients;
3 for year wise-breakdown %s are based on number of deaths within a category
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rapidly reduced and the difference in healthcare utilisa-
tion from the second year to fifth year was small. From
the second to fifth year, the mean number of days of
hospitalisation was 0.3–1.4 and the mean number of
outpatient visit was 1.4–2.5. The number of reconstruc-
tive surgery was 0.005–0.012 per patient and the num-
ber of secondary surgeries was 0.015–0.028 per patient.
The mean number of radiotherapy sessions was 0.04–
0.08 per patient and the number of chemotherapy ses-
sions was 0.04–0.09 per patient (Figure 3, 4).
Post-operative healthcare utilisation cost
Most of the costs were related to inpatient care and inpa-
tient stay was the main cost driver over the 5 year follow-
u p .F o rt h ef i v ey e a r s ,c o s to fi n p a t i e n tc a r ea c c o u n t e d
for 94.7% of the total cost. The inpatient care cost consti-
tuted of hospitalization cost( 8 4 . 8 % )a n dr e c o n s t r u c t i v e
surgery (11.4%), followed by secondary surgery (1.5%),
radiotherapy (0.9%) and chemotherapy (0.5%). Outpatient
visits accounted for 94.6% of outpatient care cost and
cost for radiotherapy and chemotherapy accounted for
4.7% and 0.7% of outpatient care cost, respectively. The
Figure 3 Mean days of hospitalisation and mean number of outpatient visit after surgery over 5 years. Year 1 yr 2 yr 3 yr 4 yr 5 yr.
Hospitalisation (days) 21.60 1.38 0.70 0.50 0.30. Number of outpatient visit 4.25 2.54 1.99 1.66 1.43.
Table 3 Total number of deaths and the estimation of survived patients by year
Year No. of
patient
followed
No. of
deaths
identified
No. of patient
censored per
year
1
Mortality
rate per
year
2
No. of death among
censored patients
3
No. of survived patient
estimated by KMSA
4
Cumulative
survival, all-causes
(%)
1
year
11,403 1,706 0 15.0% 0 11,403 -
2
year
9,697 1,044 2,046 10.8% 220 9,697 85.0%
3
year
6,607 520 1,767 7.9% 139 8,433 74.0%
4
year
4,320 274 1,592 6.3% 101 7,774 68.2%
5
year
2,454 - - - - 7,399 64.9%
1= No. of followed patient - No. of followed patient at next year - No. of death
2 = No. of death/No. of followed patient
3 = No. of censored patient * mortality rate per year
4 = No. of patient at previous year - No. of death at previous year - No. of death among censored patient at previous year
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resected patients with SCCHN was £23,212 over 5 years.
The mean cost per year was £19,778 for the first year,
£1,477 for second year, £847 for third year, £653 for
fourth year and £455 for the fifth year (Table 4). The
post-operative treatment for larynx cancer was most
costly, £28,981 over 5 years, followed by pharynx cancer
(£25,827), oral cavity cancer (£25,311), tongue cancer
(£19,493) and lip cancer (£5,790) (Table 5). The total
cost of the post-operative healthcare utilisation for the
cohort of resected SCCHN was estimated to be £255.5
million over the 5-year follow-up.
Discussion
The findings in the analysis were based on a large cohort
of patients who were resected for SCCHN between 2003
and 2009. The patient group seemed representative of
the resected SCCHN population in the UK. Rogers et al.,
estimated a 5 year survival rate by the Kaplan-Meier sur-
vival analyses among patients who underwent primary
surgery for oral cancer during 1992–2002 in the UK
[29]. Among the patients during 2000–2i nt h es t u d y ,
overall survival rates at 2 year and 5 year were 74% and
64%, respectively. In the study cohort, overall survival
rates at 2 year and 5 year were 74.0% and 64.9%, respec-
tively, and among the resected oral cancer patients (ton-
gue and oral cavity cancer only), overall survival rates at
2 year and 5 year were 74.2% and 65.7%, respectively.
According to a comparative report of Scottish and
English cohorts, a treatment modality involving surgery
for HNC treatment accounted for 51.3% and 51.6% in
both cohorts [30]. Among the 38,460 patients with
SCCHN extracted from HES data, 14,764 patients
(38.4%) of them were identified to undergo resection.
The difference might be caused by miscellaneous sur-
geries such as biopsy that was not regarded as surgical
resection in the sample selection.
In 2001, van Agthoven reported that the average cost
per patient was €21,858 for HNC and €27,629 for the
recurrent disease for two years in the Netherlands [31].
Based on 36% of the relapse rate from a prospective
cohort study of patients with SCCHN [32], the weighted
average cost would be €23,936 and it could be converted
to £23,066 in 2009 (1 Euro = 0.89 GBP) [33]. It was com-
parable to sum of mean cost per first and second year in
the results which was £21,255. Another study reported
that the cost of a major head and neck surgical case was
£32,000 in the UK in 2007, including inpatient cost,
resection/reconstructive surgery and also nursing cost,
intensive therapy unit, rehabilitation and support service
cost which were not included in this analysis [34].
One of the methodological difficulties of using the HES
data was that the outpatient care records had limited
levels of completeness in procedural and diagnostic
recording. Healthcare providers in the UK are required
to submit their patient’s records to NHS on a regular
basis. Mandatory fields in the data submission such as
patient identification details and specialty of outpatient
Figure 4 Mean number of healthcare utilisation procedures after surgery over 5 years.Y e a r1y r2y r3y r4y r5y r .S e c o n d a r yS u r g e r y
0.137 0.028 0.016 0.020 0.015. Reconstructive surgery 0.322 0.012 0.007 0.008 0.005. Radiotherapy 0.451 0.043 0.065 0.052 0.084. Chemotherapy
0.452 0.085 0.062 0.045 0.038.
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optional fields still needed to be improved [24]. Accord-
ing to the HES outpatient data quality report [35], 97%
of primary diagnosis were recorded as unknown and 93%
of the main procedure/intervention was recorded as “not
known” from the outpatient record in 2006–07. Thus,
outpatient visit for radiotherapy and chemotherapy might
be underestimated where “not known” was recorded for
radiotherapy and chemotherapy-related procedures. On
the other hand, the mean number of outpatient visit per
year seemed to be consistent with other studies. Accord-
ing to a recent study of the trend of follow-up for
patients with HNC in the UK, the number of follow-up
appointments for patients were reported to once every
3–6 months in the third year and once every 6–12
months in the fourth and fifth year [36] and the findings
were similar with the frequency of the outpatient visit
identified in the sample population.
Conclusion
This retrospective data analysis was performed and
based on a large number of empirical patient records
from in- and outpatient care, and the study population
seemed to be representative for resected SCCHN
patients in the UK. Almost 38% of SCCHN patients
underwent surgical resection and the resected patients
had a high mortality rate. The patients with SCCHN
needed considerable healthcare resources after surgical
resection, associated with substantial costs. Over the 5-
year follow-up period, 85% of costs occurred in the first
year following the first surgical resection. Since outpati-
ent-based radiotherapy and chemotherapy utilisation
seemed to be underestimated, the outpatient cost of
post-operative healthcare utilisation was likely to be
even higher. Nevertheless, the average total cost of post-
operative healthcare utilisation appeared to be compar-
able to previous studies.
Table 4 Mean cost of post-operative treatment for resected SCCHN patient per year
Followed year after resection 1 yr 2 yr 3 yr 4 yr 5 yr Grand total
Number of patients 11,403 9,697 8,433 7,774 7,399 44,706
Secondary Surgery 208 45 27 29 19 328
Reconstructive surgery 2,275 85 49 55 38 2,502
Radiotherapy 187 4 6 1 2 201
Chemotherapy 67 17 10 11 8 113
Chemo related condition
Anemia 33 6 3 2 1 45
Neutropenia 36 6 3 2 3 49
Thrombocytopenia 37 6 3 2 0 48
Nausea/Emesis 14 1 1 1 1 18
Mucositis 5 0 0 0 1 6
Pain 19 3 3 0 0 26
144 23 13 7 5 192
Inpatient stay 16,448 1,050 536 378 230 18,642
Inpatient care cost (£) 19,330 1,224 641 482 302 21,978
Outpatient visit
General surgery 16 15 16 13 13 73
Oral surgery 244 128 94 75 63 603
Restorative dentistry 24 25 17 16 13 95
Oral and maxillo facial surgery 27 20 16 16 15 94
Plastic surgery 11 6 5 5 4 31
Pain management 0 0 0 0 0 0
General medicine 27 23 23 20 16 109
Palliative medicine 14 12 9 5 8 48
Medical oncology 50 20 17 13 10 111
Radiology 1 0 0 0 0 2
414 249 198 163 143 1,167
Radiotherapy 34 4 7 5 8 57
Chemotherapy 1 0 1 3 3 9
Outpatient care cost (£) 448 254 206 172 153 1,233
Total cost (£) 19,778 1,477 847 653 455 23,212
Kim et al. Head & Neck Oncology 2011, 3:47
http://www.headandneckoncology.org/content/3/1/47
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cians and decision makers in understanding the eco-
nomic burden of managing SCCHN in the UK and also
suggests a need for new therapies that could improve
outcomes and reduce the disease burden.
Additional material
Additional file 1: Unit costs for procedures from inpatient and
outpatient care. The unit costs for the post-operative healthcare cost
were based on “the national schedule of reference costs 2008–09 for
NHS Trusts” and “Unit costs of health & social care 2009 “ published by
PSSRU.
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Table 5 Mean cost of post-operative treatment for resected SCCHN patient by cancer site
Followed year after resection Lip Tongue Oral cavity Pharynx Larynx SCCHN
Number of patients 1,250 2,167 2,372 2,304 3,310 11,403
Secondary Surgery 176 328 318 185 489 328
Reconstructive surgery 2,368 2,152 5,411 2,283 843 2,502
Radiotherapy 38 203 183 325 189 201
Chemotherapy 13 110 82 217 92 113
Chemo related condition
Anemia 4 45 53 71 37 45
Neutropenia 6 78 32 101 23 49
Thrombocytopenia 5 56 48 82 37 48
Nausea/Emesis 3 16 15 43 10 18
Mucositis 3 6 14 9 1 6
Pain 2 29 26 28 32 26
23 230 188 333 139 192
Inpatient stay 2,180 14,888 16,961 21,424 26,691 18,642
Inpatient care cost (£) 4,798 17,910 23,143 24,766 28,443 21,978
Outpatient visit
General surgery 87 66 78 61 77 73
Oral surgery 508 959 1,337 337 55 603
Restorative dentistry 38 88 206 116 29 95
Oral and maxillo facial surgery 68 167 200 52 9 94
Plastic surgery 124 22 21 22 14 31
Pain management 0 0 0 0 0 0
General medicine 107 98 101 99 130 109
Palliative medicine 9 43 39 91 45 48
Medical oncology 38 90 94 164 129 111
Radiology 1 2 2 3 1 2
980 1,535 2,078 943 490 1,167
Radiotherapy 11 46 80 107 34 57
Chemotherapy 1 2 9 11 14 9
Outpatient care cost (£) 992 1,583 2,168 1,061 538 1,233
Total cost (£) 5,790 19,493 25,311 25,827 28,981 23,212
Kim et al. Head & Neck Oncology 2011, 3:47
http://www.headandneckoncology.org/content/3/1/47
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